NUP98 – a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer

BACKGROUND: Triple Negative breast cancer (TNBC) is a poor outcome subgroup of breast cancer defined based on the absence of expression of ERα and PR and HER2 amplification. These hard to treat cancers lack targeted treatment options and are therefore treated with a standard of care (SoC) generic co...

Descripción completa

Detalles Bibliográficos
Autores principales: Mullan, Paul B., Bingham, Victoria, Haddock, Paula, Irwin, Gareth W., Kay, Elaine, McQuaid, Stephen, Buckley, Niamh E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444590/
https://www.ncbi.nlm.nih.gov/pubmed/30935371
http://dx.doi.org/10.1186/s12885-019-5407-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444590/
https://www.ncbi.nlm.nih.gov/pubmed/30935371
http://dx.doi.org/10.1186/s12885-019-5407-9

Ejemplares similares